Published in Curr Oncol on June 01, 2008
Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. Med Microbiol Immunol (2009) 1.94
Passive immunization with a nicotine-specific monoclonal antibody decreases brain nicotine levels but does not precipitate withdrawal in nicotine-dependent rats. Pharmacol Biochem Behav (2009) 0.97
Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations. Clin Med Insights Oncol (2012) 0.78
An update on the management of breast cancer in Africa. Infect Agent Cancer (2017) 0.75
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med (2006) 34.52
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med (2005) 33.60
Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med (2005) 31.48
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med (2005) 28.25
Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med (2004) 12.73
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol (1999) 11.78
Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med (2005) 10.58
Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst (2005) 8.36
HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med (2006) 5.10
Who gets adjuvant treatment for stage II and III rectal cancer? Insight from surveillance, epidemiology, and end results--Medicare. J Clin Oncol (2001) 2.43
Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol (2007) 2.33
Who gets chemotherapy for metastatic lung cancer? Chest (2000) 2.27
A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. J Clin Oncol (2007) 2.09
A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis. Ann Oncol (2005) 1.83
Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making (2002) 1.78
Estimates of the lifetime costs of breast cancer treatment in Canada. Eur J Cancer (2000) 1.61
Population variations in the initial treatment of non-small-cell lung cancer. J Clin Oncol (2004) 1.55
Estimating the cost of lung cancer diagnosis and treatment in Canada: the POHEM model. Can J Oncol (1995) 1.47
Significant progress in palliative treatment of non-small cell lung cancer in the past decade. Chest (2005) 1.43
Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Cancer (2007) 1.40
Lifetime costs of colon and rectal cancer management in Canada. Chronic Dis Can (2003) 1.28
Lung cancer: a cost and outcome study based on physician practice patterns. Dis Manag (2004) 1.00
Treatment and referral patterns for colorectal cancer. Med Care (2004) 0.99
How effective are disease-modifying drugs in delaying progression in relapsing-onset MS? Neurology (2007) 3.17
Metaplastic breast carcinoma: clinical-pathologic characteristics and HER2/neu expression. Breast Cancer Res Treat (2005) 1.33
Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. Curr Oncol (2009) 1.18
Wait times for breast cancer care. Br J Cancer (2006) 1.14
Guidelines for the diagnosis and management of carcinoid tumours. Part 1: the gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group. Curr Oncol (2006) 1.11
Can we do better in end-of-life care? The mixed management model and palliative care. Med J Aust (2001) 1.08
Independent prospective validation of the PaP score in terminally ill patients referred to a hospital-based palliative medicine consultation service. J Pain Symptom Manage (2001) 1.07
Inter-institutional pathology consultations for breast cancer: impact on clinical oncology therapy recommendations. Curr Oncol (2010) 0.99
The role of neoadjuvant (HER)2-targeted therapies in (HER)2-overexpressing breast cancers. Curr Oncol (2009) 0.98
Cost-effectiveness of interferon beta-1b in slowing multiple sclerosis disability progression. First estimates. Int J Technol Assess Health Care (2000) 0.95
Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole. Breast Cancer Res Treat (2006) 0.92
Modeling for cost-effective-adjuvant aromatase inhibitor strategies for postmenopausal women with breast cancer. Ann Oncol (2006) 0.89
Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma. Bone Marrow Transplant (2007) 0.88
Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat (2007) 0.88
The cost-utility of adjuvant chemotherapy using docetaxel and cyclophosphamide compared with doxorubicin and cyclophosphamide in breast cancer. Curr Oncol (2011) 0.86
Optimizing the management of HER2-positive early breast cancer: the clinical reality. Curr Oncol (2010) 0.84
The role of HER2-targeted therapies in women with HER2-overexpressing metastatic breast cancer. Curr Oncol (2009) 0.83
Drug-induced subacute cutaneous lupus erythematosus associated with nab-paclitaxel therapy. Curr Oncol (2013) 0.83
Identifying mental health services in clinical genetic settings. Clin Genet (2009) 0.82
Hospital-based psychiatric service utilization and morbidity in multiple sclerosis. Can J Neurol Sci (1998) 0.81
Cost-utility analysis of proton pump inhibitors and other gastro-protective agents for prevention of gastrointestinal complications in elderly patients taking nonselective nonsteroidal anti-inflammatory agents. Aliment Pharmacol Ther (2010) 0.80
Incidence of febrile neutropenia during adjuvant chemotherapy for breast cancer: a prospective study. Curr Oncol (2012) 0.78
Gastroesophageal cancer, palmar fasciitis and a matrix metalloproteinase inhibitor. Intern Med J (2002) 0.77
Chemotherapy uptake and wait times in early-stage non-small-cell lung cancer. Curr Oncol (2012) 0.77
Is adjuvant trastuzumab a cost-effective therapy for HER-2/neu-positive T1bN0 breast cancer? Ann Oncol (2013) 0.76
Canadian supportive care recommendations for the management of anemia in patients with cancer. Curr Oncol (2007) 0.76
How effective are disease-modifying drugs in delaying progression in relapsing-onset ms? Neurology (2008) 0.75
The concept of Tenju-gann, or "natural-end cancer". Cancer (1999) 0.75
Epirubicin, cisplatin, and prolonged or brief infusional 5-fluorouracil in the treatment of carcinoma of unknown primary site. Med Oncol (2001) 0.75
A piece of my mind. Lisa's stories. JAMA (1999) 0.75
The effect of substitution of sodium chloride with potassium chloride on the physicochemical, microbiological, and sensory properties of Halloumi cheese. J Dairy Sci (2012) 0.75
The effects of lesions in the lateral septal and hippocampal areas on the humoral immune response of adult female rats. Brain Behav Immun (1987) 0.75
Policy analysis model of the problem of food-borne illness. J R Soc Health (1989) 0.75
Cancer narratives: words beyond disease-a call for submissions. Curr Oncol (2013) 0.75